Breast Cancer in UAE

Description

BRCA1 and BRCA2
Approximately 10 to 15 percent of all breast cancers are thought to be familial and about one third of these cases are due to an inherited mutation in a BRCA1 or BRCA2 breast cancer susceptibility gene. BRCA1 and 2 mutations are associated with early-onset breast cancer, and some experts call for aggressive Screening of affected persons.

BRCA1 is a gene on chromosome 17 that is known to be involved in tumor suppression. A woman with certain known mutations in BRCA1 has a lifetime risk of 56 to 85 percent for breast cancer and an increased risk of ovarian cancer. Of women with breast cancer, a BRCA1 mutation has been found in 0.3 percent (one of 333) and of women in the general population, in 0.12 percent (one of 833). In Ashkenazi Jewish women (most Jewish people in the United States are of this Eastern European origin), BRCA1 mutations occur in 1 percent.

BRCA2 is another susceptibility gene for breast cancer and is found on chromosome 13. Mutations in BRCA2 confer an elevated breast cancer risk similar to that occurring with BRCA1 mutations. As with BRCA1, BRCA2 is also found in 1 percent of Ashkenazi Jewish women. A woman’s lifetime chance of developing breast and/or ovarian cancer is greatly increased if she inherits an altered BRCA1 or BRCA2 gene.

Women with an inherited alteration in one of these genes may also have an increased chance of developing colon cancer. Men with an altered BRCA1 or BRCA2 gene also have an increased risk of breast cancer (primarily if the alteration is in BRCA2), and possibly prostate cancer. Alterations in the BRCA2 gene have also been associated with an increased risk of lymphoma, melanoma, and cancers of the pancreas, gallbladder, bile duct, and stomach in some men and women.

In a family with a history of breast and/or ovarian cancer, it may be most informative to first test a family member who has the disease. If that person is found to have an altered BRCA1 or BRCA2 gene, the specific change is referred to

Reviews
Shared by: healthcareME
Stats
views:
46
rating:
not rated
reviews:
0
posted:
11/5/2009
language:
English
pages:
0
Comprehensive Genetic Analysis Breast Cancer TM deCODE Breast Cancer deCODE Breast CancerTM identifies 7 widely replicated genetic variants (SNPs) that are associated with increased risk of developing common breast cancer, independent of family history. These SNPs contribute to the incidence of anestimated 60 percent of all breast cancers. It is a novel, noninvasive, DNA-based reference laboratory test that offers physicians the opportunityto begin screening or initiate early treatment in those who are at increased risk. BRCA 1 and BRCA 2 Common Mutation BRCA 1 a n d BRCA 2 a r e t h e p r ima r y g e n e s responsible for the hereditary breast cancers. Statistics sugge s t tha t up to 10% of br e a s t c anc e r s a r e hereditary. Patients who have a strong family history of early-onset breast cancer in multiple first-degree relatives are often tested for the common mutations in the BRCA 1 and BRCA 2 genes. . BreastSafe® Test This special logic-based profiling test improves the sensitivity of breast cancer diagnosis by identifying the lumps at a very early stage before any symptoms appear. OncotypeDX Breast Cancer Assay Oncotype DX ® is a diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. It is validated for use in breast cancer patients whose disease is: l l l l Newly diagnosed Stage I or II Node-negative Estrogen receptor-positive Her 2 Gene Amplification Women with HER2-positive breast cancer (not passed to the family) have a more aggressive disease, greater likelihood of recurrence, poorer prognosis, and decreased survival compared to women with HER2-negative breast cancer. It is thus an important diagnosis for the treatment of breast cancer. Oncotype DX offers clinical experience information for newly diagnosed women who are post-menopausal and have node positive, estrogen receptor positive breast cancer and who will be treated with tamoxifen. EASTERN BIOTECH & l i f e s c i e n c e s P.O.Box 212671, Dubai, UAE. Tel: +971 4 369 2061 Fax: +971 4 363 1923 email:info@easternbiotech.com visit: www.easternbiotech.com Eastern Biotech & Life Sciences

Related docs
Breast Cancer
Views: 57  |  Downloads: 5
Breast Cancer
Views: 14  |  Downloads: 0
Breast Cancer
Views: 57  |  Downloads: 1
About Breast Cancer
Views: 56  |  Downloads: 0
Breast Cancer
Views: 48  |  Downloads: 2
Breast Cancer Awareness
Views: 67  |  Downloads: 0
Breast Cancer
Views: 0  |  Downloads: 0
BREAST CANCER
Views: 5  |  Downloads: 0
BREAST CANCER
Views: 2  |  Downloads: 0
BREAST CANCER
Views: 26  |  Downloads: 2
Breast_Cancer
Views: 1  |  Downloads: 0
premium docs
Other docs by healthcareME